The purpose of this study is to demonstrate an improvement in physical functional recovery, following administration of Drug for 24 weeks, in patients who have recently experienced a hip fracture. This study will also evaluate the safety and tolerability of Drug. This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
83
Msd Sharp & Dohme Gmbh
Haar, Germany
MSD (Norge) AS
Drammen, Norway
Merck Sharp & Dohme De Espana, S.A.E.
Madrid, Madrid, Spain
Merck Sharp & Dohme (Sweden) AB
Sollentuna, Sweden
Proprietary Information - Exploratory (Non-Confirmatory) Trial
Proprietary Information - Exploratory (Non-Confirmatory) Trial
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Merch Sharp & Dohme Ltd.
Hoddesdon, Hertfordshire, United Kingdom